叔-丁氧基羰基-苯基丙氨酰-亮氨酰-苯基丙氨酰-亮氨酰-苯基丙氨酰-OH | 148182-34-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 叔-丁氧基羰基-苯基丙氨酰-亮氨酰-苯基丙氨酰-亮氨酰-苯基丙氨酰-OH
• 英文名称: Boc-FLFLF
• 英文别名: Boc-2；Boc-phe-leu-phe-leu-phe；(2S)-2-[[(2S)-4-methyl-2-[[(2S)-2-[[(2S)-4-methyl-2-[[(2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]amino]pentanoyl]amino]-3-phenylpropanoyl]amino]pentanoyl]amino]-3-phenylpropanoic acid
• CAS: 148182-34-7
• 化学式: C₄₄H₅₉N₅O₈
• mdl: MFCD00076350
• 分子量: 785.981
• InChiKey: NGNZQSPFQJCBJQ-LTLCPEALSA-N

物化性质

• 沸点：
  1043.2±65.0 °C(Predicted)
• 密度：
  1.167±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  57
• 可旋转键数：
  22
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  192
• 氢给体数：
  6
• 氢受体数：
  8

制备方法与用途

生物活性方面，N-Boc-Phe-Leu-Phe-Leu-Phe（Boc-FLFLF）是一种甲酰肽受体 1 (FPR1) 拮抗剂多肽。其主要生理功能是增加疼痛作用并抑制膜联蛋白的抗疼痛活性。

该多肽由5个疏水性氨基酸组成，N端被Boc封闭，具有较强的疏水性。

参考质量标准如下：

• 外观：白色粉末
• 纯度（HPLC）≥98.0%
• 醋酸根含量≤12.0%
• 水分含量≤8.0%
• 肽含量≥80.0%
• 内毒素≤50EU/mg
• 氨基酸组成分析误差≤±10%

反应信息

• 作为反应物：
  描述：

  盐酸 、 L-苯丙氨酸 、 o-Phthalaldehyde 2-mercaptoethanol 、 叔-丁氧基羰基-苯基丙氨酰-亮氨酰-苯基丙氨酰-亮氨酰-苯基丙氨酰-OH 以 甲醇 为溶剂， 反应 20.42h， 生成 邻苯二甲醛
  参考文献：
  名称：

  Dense star polymer conjugates as dyes

  摘要：

  已经制备了至少由一个树状分子与至少一个携带的农业、制药或其他材料单元组成的星形共轭物。由于树状分子的独特特性，这些共轭物具有特别优越的性质。

  公开号：

  US06312679B1
• 作为产物：
  描述：

  Boc-Phe-Leu-Phe-Leu-Phe-O-t-Bu 在 cross-linked enzyme aggregates of Alcalase 、 水 作用下， 以 1,4-二氧六环 为溶剂， 反应 37.0h， 以78%的产率得到叔-丁氧基羰基-苯基丙氨酰-亮氨酰-苯基丙氨酰-亮氨酰-苯基丙氨酰-OH
  参考文献：
  名称：

  使用C-末端叔-丁基酯相互转化的全酶肽合成

  摘要：

  化学酶促肽合成可能是合成短和中等大小肽的最经济有效的技术，具有一些重要的优势。例如，不需要化学计量的昂贵偶联剂，也不会发生外消旋化，因此与化学肽合成相比，纯化更加容易。经济上最具吸引力的合成是在NC末端方向进行的，其中廉价的C末端保护的氨基酸被用作延伸的基础。然而，延长步骤后的C末端脱保护和激活-不会裂解侧链保护基或肽键-仍然是一个挑战。在本文中，我们描述了一种新颖的C丝氨酸内肽酶Alcalase催化末端酯的相互转化。C-末端保护的肽叔丁酯以定量收率被酶促转化为伯烷基酯，并与另一种氨基酸叔丁酯直接用于下一步的酶促延伸步骤。通过C-末端酯互变的这种完全酶促NC延伸策略被用于合成高达五聚体水平的生物活性肽。

  DOI：

  10.1002/adsc.201000313

文献信息

• Dense star polymer conjugates
  申请人：The Dow Chemical Company

  公开号：US05527524A1

  公开（公告）日：1996-06-18

  Dense star polymer conjugates which are composed of at least one dendrimer in association with at least one unit of a carried agricultural, pharmaceutical, or other material have been prepared. These conjugates have particularly advantageous properties due to the unique characteristics of the dendrimer.

  已经制备了由至少一种树状分子与至少一种携带农业、制药或其他物质的单元组成的致密星形聚合物共轭物。由于树状分子的独特特性，这些共轭物具有特别优越的性质。
• Bioactive and/or targeted dendrimer conjugates
  申请人：The Dow Chemical Company

  公开号：US05714166A1

  公开（公告）日：1998-02-03

  Dendritic polymer conjugates which are composed of at least one dendrimer in association with at least one unit of a carried material, where the carrier material can be a biological response modifier, have been prepared. The conjugate can also have a target director present, and when it is present then the carried material may be a bioactive agent. Preferred dendritic polymers are dense star polymers, which have been complexed with biological response modifiers. These conjugates and complexes have particularly advantageous properties due to their unique characteristics.

  已经制备了由至少一种树状聚合物与至少一种携带材料单元组成的树状聚合物共轭物，其中携带材料可以是生物反应修饰剂。该共轭物也可以具有目标指示器，当存在目标指示器时，所携带的材料可以是生物活性剂。优选的树状聚合物是密集的星形聚合物，已经与生物反应修饰剂形成复合物。这些共轭物和复合物由于其独特的特性具有特别有利的性质。
• Dense star polymer conjugates as dyes
  申请人：The Dow Chemical Company

  公开号：US06312679B1

  公开（公告）日：2001-11-06

  Starburst conjugates which are composed of at least one dendrimer in association with at least one unit of a carried agricultural, pharmaceutical, or other material have been prepared. These conjugates have particularly advantageous properties due to the unique characteristics of the dendrimer.

  已经制备了至少由一个树状分子与至少一个携带的农业、制药或其他材料单元组成的星形共轭物。由于树状分子的独特特性，这些共轭物具有特别优越的性质。
• d-Peptide analogues of Boc-Phe-Leu-Phe-Leu-Phe-COOH induce neovascularization via endothelial N-formyl peptide receptor 3
  作者：Mohd I. Nawaz、Sara Rezzola、Chiara Tobia、Daniela Coltrini、Mirella Belleri、Stefania Mitola、Michela Corsini、Annamaria Sandomenico、Andrea Caporale、Menotti Ruvo、Marco Presta

  DOI：10.1007/s10456-020-09714-0

  日期：2020.8

  N-formyl peptide receptors (FPRs) are G protein-coupled receptors involved in the recruitment and activation of immune cells in response to pathogen-associated molecular patterns. Three FPRs have been identified in humans (FPR1-FPR3), characterized by different ligand properties, biological function and cellular distribution. Recent findings from our laboratory have shown that the peptide BOC-FLFLF (l-BOC2), related to the FPR antagonist BOC2, acts as an angiogenesis inhibitor by binding to various angiogenic growth factors, including vascular endothelial growth factor-A(165)(VEGF). Here we show that the all-d-enantiomer ofl-BOC2 (d-BOC2) is devoid of any VEGF antagonist activity. At variance,d-BOC2, as well as thed-FLFLF and succinimidyl (Succ)-d-FLFLF (d-Succ-F3)d-peptide variants, is endowed with a pro-angiogenic potential. In particular, thed-peptided-Succ-F3 exerts a pro-angiogenic activity in a variety of in vitro assays on human umbilical vein endothelial cells (HUVECs) and in ex vivo and in vivo assays in chick and zebrafish embryos and adult mice. This activity is related to the capacity ofd-Succ-F3 to bind FRP3 expressed by HUVECs. Indeed, the effects exerted byd-Succ-F3 on HUVECs are fully suppressed by the G protein-coupled receptor inhibitor pertussis toxin, the FPR2/FPR3 antagonist WRW4 and by an anti-FPR3 antibody. A similar inhibition was observed following WRW4-induced FPR3 desensitization in HUVECs. Finally,d-Succ-F3 prevented the binding of the anti-FPR3 antibody to the cell surface of HUVECs. In conclusion, our data demonstrate that the angiogenic activity ofd-Succ-F3 is due to the engagement and activation of FPR3 expressed by endothelial cells, thus shedding a new light on the biological function of this chemoattractant receptor.
• Bmp Gene and Fusion Protein
  申请人：Hidaka Chisa

  公开号：US20080260829A1

  公开（公告）日：2008-10-23

  This invention relates to BMP fusion genes, BMP fusion proteins. The invention further relates to methods for treatment using BMP fusion genes and BMP fusion proteins. Additionally, the invention relates to BMP fusion gene and BMP fusion protein pharmaceutical compositions.